Sanofi SA banner

Sanofi SA
PAR:SAN

Watchlist Manager
Sanofi SA Logo
Sanofi SA
PAR:SAN
Watchlist
Price: 80.33 EUR -1.75% Market Closed
Market Cap: €97.4B

SAN's latest stock split occurred on May 24, 1999

The company executed a 4-for-1 stock split, meaning that for every share held, investors received 4 new shares.

The adjusted shares began trading on May 24, 1999. This was SAN's 5th stock split, following the previous one in Oct 2, 1995.

Last Splits:
May 24, 1999
4-for-1
Oct 2, 1995
11-for-10
Sep 27, 1994
4-for-1
Jun 5, 1992
989-for-967
Jun 10, 1991
769-for-747
Pre-Split Price
N/A
Post-Split Price
37.5907
Before
After
Last Splits:
May 24, 1999
4-for-1
Oct 2, 1995
11-for-10
Sep 27, 1994
4-for-1
Jun 5, 1992
989-for-967
Jun 10, 1991
769-for-747

Sanofi SA
Stock Splits History

SAN Stock Splits Timeline
May 24, 1999
May 24, 1999
Split 4-for-1
x4
Pre-Split Price
N/A
Post-Split Price
37.5907
Before
After
Oct 2, 1995
Oct 2, 1995
Split 11-for-10
x1.1
Pre-Split Price
N/A
Post-Split Price
37.5907
Before
After
Sep 27, 1994
Sep 27, 1994
Split 4-for-1
x4
Pre-Split Price
N/A
Post-Split Price
37.5907
Before
After
Jun 5, 1992
Jun 5, 1992
Split 989-for-967
x1.0227507755946
Pre-Split Price
N/A
Post-Split Price
37.5907
Before
After
Jun 10, 1991
Jun 10, 1991
Split 769-for-747
x1.0294511378849
Pre-Split Price
N/A
Post-Split Price
37.5907
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Apr 24, 2026
Medical Data Vision Co Ltd
TSE:3902
2-for-7253607
/3626803.5
1684 1684 JPY N/A
Apr 24, 2026
Metro Mining Ltd
ASX:MMI
1-for-20
/20
0.067 1.34 AUD 1.3 1.3 AUD
Apr 23, 2026
Red Sky Energy Ltd
ASX:ROG
5-for-4
x1.25
0.002 0.0016 AUD 0.002 0.002 AUD
Apr 23, 2026
S
Saudee Group Bhd
KLSE:SAUDEE
1-for-10
/10
0.01 0.1 MYR 0.09 0.09 MYR
Apr 23, 2026
Focus Technology Co Ltd
SZSE:002315
1-for-1
x1
44.3999 33.4538 CNY 32 32 CNY
Load More

Sanofi SA
Glance View

Sanofi SA, a titan in the global healthcare sector, operates at the intricate crossroads of pharmaceutical innovation and patient care, driven by an unyielding commitment to improving human health. Emerging from its French roots, Sanofi has strategically positioned itself as a global leader in pharmaceuticals, vaccines, and consumer healthcare. The company’s success is essentially anchored in its capacity to consistently develop and commercialize life-saving drugs that address a myriad of health concerns, ranging from diabetes and cardiovascular diseases to rare disorders and oncology. Underlining its robust revenue engine is Sanofi's extensive R&D infrastructure that fuels its pipeline with groundbreaking therapies, reflecting a dynamic blend of scientific acumen and market-focused agility. By leveraging a hybrid model that integrates cutting-edge research with strategic alliances and acquisitions, Sanofi ensures a sustained presence in the highly competitive biopharmaceutical landscape. Enabling this network of innovation and impact is Sanofi's diverse portfolio, a balanced mix of specialty and established prescription drugs, over-the-counter products, and the critical arm of vaccines led by its Sanofi Pasteur division. This diversification offers both growth opportunities and stability, cushioning against the volatile tides of patent expirations and regulatory changes. Its vaccines segment, in particular, is a cornerstone in Sanofi's business, capturing substantial market share with products critical to global immunization efforts, further amplified by its role in responding to health emergencies like the COVID-19 pandemic. With a geographically expansive sales footprint and strategic marketing strategies, Sanofi capitalizes on emerging market opportunities while maintaining a strong presence in established regions, effectively making its bottom line a testimony to its operational excellence and strategic foresight in harmonizing science with humanity.

SAN Intrinsic Value
110.42 EUR
Undervaluation 27%
Intrinsic Value
Price €80.33
Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett